Sharp Therapeutics Corp
Sharp Therapeutics Corp is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic products and services.
Business. Sharp Therapeutics Corp (SHRX.V) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in Canada and is primarily listed on the TSX Venture Exchange. As segment and geographic breakdowns are not provided, the company is described at the industry level.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Sharp Therapeutics Corp (SHRX.V) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in Canada and is primarily listed on the TSX Venture Exchange. As segment and geographic breakdowns are not provided, the company is described at the industry level.
Sharp Therapeutics Corp has a highly liquid balance sheet, with a current ratio of 11.6, indicating strong short-term liquidity. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. However, the company is experiencing negative cash flows, with an operating cash flow of -$15,364 million and a free cash flow of -$21,098 million, which may pressure liquidity over time.
Profitability metrics are negative, with a return on equity of -8.33% and a return on assets of -7.61%. These figures are below the industry median for biotechnology and medical research firms, indicating underperformance relative to peers. The company reported a net loss of $21,098 million, which is a significant drag on shareholder value.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial filings. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare diagnostics sector, which is subject to regulatory and reimbursement pressures.
Growth trajectory is currently negative, with the company reporting declining operating income and net income. There are no disclosed plans for significant revenue growth in the near term, and the company is not investing in capital expenditures, as long-term debt remains at zero. This suggests a lack of investment in future growth opportunities.
Risk factors include liquidity risk due to negative operating and free cash flows, though the company has no immediate filing-based liquidity or dilution flags. The absence of long-term debt and a low dilution risk score provide some buffer, but the company's financial performance remains a concern.
Recent events include the latest financial filing, which shows continued losses and negative cash flows. There are no disclosed material events or regulatory actions in the latest filings, but the company's financial position remains weak.
- Sharp Therapeutics Corp has a highly liquid balance sheet with a current ratio of 11.6.
- The company is unprofitable, with a return on equity of -8.33% and a return on assets of -7.61%.
- Revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
- The company is experiencing negative cash flows, with no long-term debt and no capital expenditures.
- There are no immediate liquidity or dilution flags, but financial performance remains a concern.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Sharp Therapeutics Corp Market data — financials · 2026-05-29